The clinical significance of increased plasma levels of liver-synthesized coagulation factors in liver disease.
The first plasma Factor II-VII-X value after admission to the hospital was higher than 90% in 29% of 38 common duct stone patients, in 9% of 33 patients with bile duct obstruction due to pancreatic carcinoma, and in 3 of 5 patients with cholestatic drug reaction. In contrast, the admission value was above 90% in only one of 89 patients with acute hepatitis and in none of 8 patients with a hepatocellular drug reaction. Therefore, a high plasma Factor II-VII-X activity in a patient with liver or biliary tract disease seems to be a rellained by an increased protein synthesis in the liver.
D000082:Acetaminophen / Q000506:poisoning; D000208:Acute Disease; D001660:Biliary Tract Diseases / Q000097:blood*; D001779:Blood Coagulation Factors / Q000032:analysis; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood; D002746:Chlorpromazine / Q000009:adverse effects; D002779:Cholestasis / Q000097:blood; D005167:Factor VII / Q000032:analysis; D005170:Factor X / Q000032:analysis; D042882:Gallstones / Q000097:blood; D006525:Hepatitis, Viral, Human / Q000097:blood; D006801:Humans; D008107:Liver Diseases / Q000097:blood*; D010190:Pancreatic Neoplasms / Q000097:blood; D011516:Prothrombin / Q000032:analysis
D001779:Blood Coagulation Factors; D000082:Acetaminophen; D005167:Factor VII; D011516:Prothrombin; D005170:Factor X; D002746:Chlorpromazine